A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Conditions

• Relapsed/Refractory Advanced Solid Tumors
• Relapsed/Refractory Diffuse Large B-cell Lymphoma
• Relapsed/Refractory Myelodysplasia
• Relapsed/Refractory Myelofibrosis
• Adenoid Cystic Carcinoma
• Relapsed/Refractory Mantle Cell Lymphoma
• Relapsed/Refractory Acute Myeloid Leukemia
• Refractory Chronic Myelomonocytic Leukemia

Interventions

• DRUG: PRT543

Sponsor

Prelude Therapeutics